Our previous work with human breast cancer cell lines showed that the combined inhibition of FGFR and ErbB receptors caused a complete loss of PI3K/Akt/mTOR pathway activity and a robust block in in vitro proliferation [35]. The gene discussed is MTOR; the disease is breast carcinoma.